Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro

Molecular and Cellular Biochemistry

Volumn 406, Issue 1-2, 2015, Pages 63-73

  Li, Weidong ^a,c   Saud, Shakir M ^b,c   Young, Matthew R ^c   Colburn, Nancy H ^c   Hua, Baojin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Colorectal cancer treatment; Cryptotanshinone; Proliferation; Signal transducer and activator of transcription 3

Indexed keywords

CASPASE 3; CRYPTOTANSHINONE; CYCLIN D1; PROTEIN P21; PROTEIN P27; STAT3 PROTEIN; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INHIBITOR OF APOPTOSIS PROTEIN; PHENANTHRENE DERIVATIVE; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HCT116 CELL LINE; METABOLISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PHENANTHRENES; STAT3 TRANSCRIPTION FACTOR;

EID: 84945950271     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2424-0     Document Type: Article

References (57)

1. Inoue-Choi M, Lazovich D, Prizment AE, Robien K (2013) Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention is associated with better health-related quality of life among elderly female cancer survivors. J Clin Oncol 31:1758–1766. doi:10.1200/JCO.2012.45.4462
2. Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191–197. doi:10.1055/s-0029-1242458
3. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499–2513. doi:10.1038/sj.onc.1204349
4. Germain D, Frank DA (2007) Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13:5665–5669. doi:10.1158/1078-0432.CCR-06-2491
5. Lau GK, Ye D (2010) STAT3 implicated in the development of colon cancer: a step closer for targeted therapy? Gastroenterology 139:353–355. doi:10.1053/j.gastro.2010.05.030
6. Chen X, Du Y, Nan J, Zhang X, Qin X, Wang Y, Hou J, Wang Q, Yang J (2013) Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS ONE 8:e63697. doi:10.1371/journal.pone.0063697
7. Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, Ogino S (2011) STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17:1452–1462. doi:10.1158/1078-0432.CCR-10-2694
8. Ma Y, Li H, Yue Z, Guo J, Xu S, Xu J, Jia Y, Yu N, Zhang B, Liu S, Liu M, Shao W, Chen S, Liu P (2014) Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2 and NOX-4. J Cardiovasc Pharmacol. doi:10.1097/FJC.0000000000000086
9. Tang Y, Chen Y, Chu Z, Yan B, Xu L (2014) Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 723:494–500. doi:10.1016/j.ejphar.2013.10.019
10. Zheng FL, Chang Y, Jia XY, Huang M, Wei W (2011) Effects and mechanisms of Cryptotanshinone on rats with adjuvant arthritis. Chin Med J (Engl) 124:4293–4298
11. Chen W, Liu L, Luo Y, Odaka Y, Awate S, Zhou H, Shen T, Zheng S, Lu Y, Huang S (2012) Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. Cancer Prev Res (Phila) 5:778–787. doi:10.1158/1940-6207.CAPR-11-0551
12. Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, Shen T, Liu Z, Lu Y, Huang S (2010) Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila) 3:1015–1025. doi:10.1158/1940-6207.CAPR-10-0020
13. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69:193–202. doi:10.1158/0008-5472.CAN-08-2575
14. Ge Y, Cheng R, Zhou Y, Shen J, Peng L, Xu X, Dai Q, Liu P, Wang H, Ma X, Jia J, Chen Z (2012) Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem 368:17–25. doi:10.1007/s11010-012-1338-3
15. Kim JH, Jeong SJ, Kwon TR, Yun SM, Jung JH, Kim M, Lee HJ, Lee MH, Ko SG, Chen CY, Kim SH (2011) Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 16:696–707. doi:10.1007/s10495-011-0605-1
16. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47–59. doi:10.1038/nrm2308
17. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337. doi:10.1038/sj.onc.1210220
18. Bai L, Chen J, McEachern D, Liu L, Zhou H, Aguilar A, Wang S (2014) BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS ONE 9:e99404. doi:10.1371/journal.pone.0099404
19. Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, Peng J, You Y, Zhang X, Shen X (2013) Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling. Mol Cell Biochem 381:273–282. doi:10.1007/s11010-013-1711-x
20. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295–303
21. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J (2011) STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 71:7226–7237. doi:10.1158/0008-5472.CAN-10-4660
22. Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T, Lin J (2011) STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem Biophys Res Commun 416:246–251. doi:10.1016/j.bbrc.2011.10.112
23. Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z, Jia X, Jiang T, Zhang J, Li X, Kang C, Ren H (2014) JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro Oncol 16:1229–1243. doi:10.1093/neuonc/nou046
24. Klampfer L (2006) Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6:107–121
25. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15:1445–1451
26. Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:1535–1542. doi:10.1182/blood-2002-07-2130
27. Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J, Wang X, Zhong X, Wang S (2014) Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol 7:7989–7998
28. Krecicki T, Smigiel R, Fraczek M, Kowalczyk M, Sasiadek MM (2004) Studies of the cell cycle regulatory proteins P16, cyclin D1 and retinoblastoma protein in laryngeal carcinoma tissue. J Laryngol Otol 118:676–680. doi:10.1258/0022215042244769
29. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6:24. doi:10.1186/1476-4598-6-24
30. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70. doi:10.1038/nrc2293
31. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400–414. doi:10.1038/nrc2657
32. Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10:51–57. doi:10.1038/nrc2772
33. Majumder PK, Grisanzio C, O’Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR (2008) A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14:146–155. doi:10.1016/j.ccr.2008.06.002
34. Freedman VH, Shin SI (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3:355–359
35. Zhou L, Zuo Z, Chow MS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345–1359. doi:10.1177/0091270005282630
36. Lee HJ, Jung DB, Sohn EJ, Kim HH, Park MN, Lew JH, Lee SG, Kim B, Kim SH (2012) Inhibition of hypoxia inducible factor alpha and astrocyte-elevated gene-1 mediates cryptotanshinone exerted antitumor activity in hypoxic PC-3 cells. Evid Based Complement Alternat Med 2012:390957. doi:10.1155/2012/390957
37. Park IJ, Kim MJ, Park OJ, Park MG, Choe W, Kang I, Kim SS, Ha J (2010) Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett 298:88–98. doi:10.1016/j.canlet.2010.06.006
38. Chen L, Zheng SZ, Sun ZG, Wang AY, Huang CH, Punchard NA, Huang SL, Gao X, Lu Y (2011) Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity. Cancer Chemother Pharmacol 68:17–27. doi:10.1007/s00280-010-1440-8
39. Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, Chang C, Yeh S (2012) Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett 316:11–22. doi:10.1016/j.canlet.2011.10.006
40. Song M, Hang TJ, Zhang Z, Chen HY (2007) Effects of the coexisting diterpenoid tanshinones on the pharmacokinetics of cryptotanshinone and tanshinone IIA in rat. Eur J Pharm Sci 32:247–253. doi:10.1016/j.ejps.2007.07.007
41. Liu Y, Li X, Li Y, Wang L, Xue M (2010) Simultaneous determination of danshensu, rosmarinic acid, cryptotanshinone, tanshinone IIA, tanshinone I and dihydrotanshinone I by liquid chromatographic-mass spectrometry and the application to pharmacokinetics in rats. J Pharm Biomed Anal 53:698–704. doi:10.1016/j.jpba.2010.03.041
42. Xie MZ, Shen ZF (1983) Absorption, distribution, excretion and metabolism of cryptotanshinone. Yao Xue Xue Bao 18:90–96
43. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171:59–76. doi:10.1111/j.1749-6632.2009.04911.x
44. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552–5560. doi:10.1038/sj.onc.1208719
45. Xu JH, Zhang C, Tang B, Hao YX, Chen J, Liu T, Cui H (2010) Effect of JAK2/STAT3/vimentin signaling pathway on proliferation and migration of human colon cancer cells. Zhonghua Wei Chang Wai Ke Za Zhi 13:282–285
46. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschlager P, Schutz A, Halbhuber KJ, Friedrich K (2005) Persistent Stat3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7:545–555
47. Chen L, Wang HJ, Xie W, Yao Y, Zhang YS, Wang H (2014) Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo. Mol Med Rep 9:2447–2452. doi:10.3892/mmr.2014.2093
48. Harada D, Takigawa N, Kiura K (2014) The role of STAT3 in non-small cell lung cancer. Cancers (Basel) 6:708–722. doi:10.3390/cancers6020708
49. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP Jr (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107:351–362. doi:10.1172/JCI9940
50. Shen Y, Devgan G, Darnell JE Jr, Bromberg JF (2001) Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 98:1543–1548. doi:10.1073/pnas.041588198
51. Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740–749. doi:10.1038/nrc906
52. Kan WL, Yin C, Xu HX, Xu G, To KK, Cho CH, Rudd JA, Lin G (2013) Antitumor effects of novel compound, guttiferone K, on colon cancer by p21Waf1/Cip1-mediated G(0)/G(1) cell cycle arrest and apoptosis. Int J Cancer 132:707–716. doi:10.1002/ijc.27694
53. Russo A, Esposito D, Catillo M, Pietropaolo C, Crescenzi E, Russo G (2013) Human rpL3 induces G(1)/S arrest or apoptosis by modulating p21 (waf1/cip1) levels in a p53-independent manner. Cell Cycle 12:76–787. doi:10.4161/cc.22963
54. Zhang M, Truscott J, Davie J (2013) Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol Cancer 12:150. doi:10.1186/1476-4598-12-150
55. Huang L, Wang HY, Li JD, Wang JH, Zhou Y, Luo RZ, Yun JP, Zhang Y, Jia WH, Zheng M (2013) KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a. Cell Death Dis 4:e745. doi:10.1038/cddis.2013.256
56. Lee WY, Cheung CC, Liu KW, Fung KP, Wong J, Lai PB, Yeung JH (2010) Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J Nat Prod 73:854–859. doi:10.1021/np900792p
57. Ye Y, Xu W, Zhong W (2010) Effects of cryptotanshinone on proliferation and apoptosis of Hela cell line of cervical cancer. Zhongguo Zhong Yao Za Zhi 35:118–121